Rho-kinase as a potential therapeutic target for the treatment of pulmonary hypertension

Drug News and Perspectives

Volumn 19, Issue 9, 2006, Pages 517-522

  Xing, Xi Qian ^a   Gan, Ye ^a   Wu, Shang Jie ^a   Chen, Ping ^a   Zhou, Rui ^a   Xiang, Xu Dong ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; FASUDIL; INDAZOLE DERIVATIVE; MONOCROTALINE; RHO FACTOR; RHO KINASE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UREA DERIVATIVE;

APOPTOSIS; BLOOD PRESSURE; CELL MIGRATION; CELL PROLIFERATION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; FLUSHING; HEADACHE; HUMAN; HYPOXIA; LUNG VASOCONSTRICTION; MUSCLE FIBER CONTRACTION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

ANIMALS; HUMANS; HYPERTENSION, PULMONARY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RHOA GTP-BINDING PROTEIN;

EID: 33846496061     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.9.1050426     Document Type: Review

References (72)

1. Zaiman, A., Fijalkowska, I., Hassoun, P.M. and Tuder, R.M. One hundred years of research in the pathogenesis of pulmonary hypertension. Am J Respir Cell Mol Biol 2005, 33: 425-31.
2. Guilluy, C., Sauzeau, V., Derkinderen, M.R. et al. Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. Br J Pharmacol 2005, 146: 1010-8.
3. Hyvelin, J.M., Howell, K., Nichol, A., Costello, C.M., Preston, R.J. and McLoughlin. P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005, 97: 185-91.
4. Nagaoka, T., Fagan, K.A., Gebb, S.A. et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hvpertension. Am J Respir Crit Care Med 2005, 171: 494-9.
5. Nagaoka, T., Gebb, S.A., Karoor, V. et al. Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat. J Appl Physiol 2006, 100: 996-1002.
6. Fagan, K.A., Oka, M., Bauer, N.R. et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rhokinase. Am J Physiol Lung Cell Mol Physiol 2004, 287: L656-64.
7. Abe, K., Shimokawa, H., Morikawa, K. et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004, 94: 385-93.
8. Milburn, M.V., Tong, L., deVos, A.M. et al. Molecular switch for signal transduction: structural differences between active and inactive forms of protooncogenic ras proteins. Science 1990, 247: 939-45.
9. Zheng, Y., Olson, M.F., Hall, A., Cerione, R.A. and Toksoz, D. Direct involvement of the small GTP-binding protein Rho in lbc oncogene function. J Biol Chem 1995, 270: 9031-4.
10. Fauré, J. and Dagher M.C. Interactions between Rho GTPases and Rho GDP dissociation inhibitor (Rho-GDI). Biochimie 2001, 83: 409-14.
11. Lancaster, C.A., Taylor-Harris, P.M., Self, A.J., Brill, S., van Erp, H.E. and Hall, A. Characterization of rhoGAP. A GTPase-activating protein for rho-related small GTPases. J Biol Chem 1994, 269: 1137-42.
12. Boguski, M.S. and McCormick, F. Proteins regulating Ras and its relatives. Nature 1993, 366: 643-54.
13. Etienne-Manneville, S. and Hall, A. Rho GTPases in cell biology. Nature 2002, 420: 629-35.
14. Van Aelst, L. and D'Souza-Schorey, C. Rho GTPases and signaling networks. Genes Dev 1997, 11: 2295-322.
15. Matsui, T., Amano, M., Yamamoto, T. et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996, 15: 2208-16.
16. Leung, T., Chen, X.Q., Manser, E. and Lim, L. The p160 RhoA-binding kinase RoKalpha is a member of a kinase family and is involved in the reorganization of a kinase family and is involved in the reorganization of the cytoskeleton. Mol Cell Biol 1996, 16: 5313-27.
17. Leung, T., Manser, E., Tan, L. and Lim, L. A novel serine/threonine kinase binding the Ras-related RhoA GTPase which translocates the kinase to peripheral membranes. J Bio Chem 1995, 270: 29051-4.
18. Nakagawa, O., Fujisawa, K., Ishizaki, T., Saito, Y., Nakao, K. and Narumiya, S. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett 1996, 392: 189-93.
19. Kimura, K., Ito, M., Amano, M. et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase(Rho-kinase). Science 1996, 273: 245-8.
20. Wang, P. and Bitar, K.N. Rho A regulates sustained smooth muscle contraction through cytoskeletal reorganization of HSP27. Am J Physiol 1998, 275: G1454-62.
21. Kozai, T., Eto, M., Yang, Z., Shimokawa, H. and Luscher, T.F. Statins prevent pulsatile stretch-induced proliferation of human saphenous vein smooth muscle cells via inhibition of Rho/Rho-kinase pathway. Cardiovasc Res 2005, 68: 475-82.
22. Moore, M., Marroquin, B.A., Gugliotta, W., Tse, R. and White, S.R. Rho kinase inhibition initiates apoptosis in human airway epithelial cells. Am J Respir Cell Mol Biol 2004, 30: 379-87.
23. Khan, I., Oriowo, M.A., Chandrasekhar, B. and Kadavil, E.A. Attenuated noradrenaline-induced contraction of pulmonary arteries from rats treated with monocrotaline: role of Rho Kinase. J Vasc Res 2005, 42: 433-40.
24. 2+ desensitization in pulmonary vascular smooth muscle through inhibition of RhoA/Rho kinase signaling. Am J Physiol Lung Cell Mol Physiol 2004, 287: L1220-9.
25. Bailly, K., Ridley, A.J., Hall, S.M. and Haworth, S.G. RhoA activation by hypoxia in pulmonary arterial smooth muscle cells is age and site specific. Circ Res 2004, 94: 1383-91.
26. Uehata, M., Ishizaki, T., Satoh, H. et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 389: 990-4.
27. Budzyn, K., Marley, P.D. and Sobey, C.G. Opposing roles of endothelial and smooth muscle phosphatidylinositol 3-kinase in vasoconstriction: effects of rho-kinase and hypertension. J Pharmacol Exp Ther 2005, 313: 1248-53.
28. Robertson, T.P., Dipp, M., Ward, J.P., Aaronson, P.I. and Evans, A.M. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 2000, 131: 5-9.
29. Ishizaki, T., Uehata, M., Tamechika, I. et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000, 57: 976-83.
30. Asano, T., Ikegaki, I., Satoh, S. et al. Mechanism of action of a novel antivasospasm drug, HA1077. J Pharmacol Exp Ther 1987, 241: 1033-40.
31. Shimokawa, H., Seto, M., Katsumata, N. et al. Rho-kinase pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 1999, 43: 1029-39.
32. Tachibana, E., Harada, T., Shibuya, M. et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 1999, 141: 13-9.
33. Fukumoto, Y., Matoba, T., Ito, A. et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005, 91: 391-2.
34. Ishikura, K., Yamada, N., Ito, M. et al. Beneficial acute effects of Rho-Kinase inhibitor in patients with pulmonary arterial hypertension. Circ J 2006, 70: 174-8.0
35. Takami, A., Iijima, H., Iwakubo, M. and Okada, Y. Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same. European Patent 2001, EP1256574A1.
36. Fonseca, J.C., Balzano, C.D. and de Leon, R.S. Endothelial dysfunction in pulmonary hypertension. Arch Bronconeumol 2005, 41: 389-92.
37. Cella, G, Bellotto, F., Tona, F. et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest 2001, 120: 1226-30.
38. Tuder, R.M., Cool, C.D., Geraci, M.W. et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159: 1925-32.
39. Frasch, H.F., Marshall, C. and Marshall, B.E. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999, 276: L304-10.
40. Giaid, A., Yanagisawa, M., Langleben, D. et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993, 328: 1732-9.
41. Hubloue, I., Biarent, D., Abdel Kafi, S. et al. Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction. Eur Respir J 2003, 21: 19-24.
42. Ozaki, M., Kawashima, S., Yamashita, T. et al. Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium. Hypertension 2001, 37: 322-7.
43. Smith, A.P., Demoncheaux, E.A. and Higenbottam, T.W. Nitric oxide gas de endothelin-1 mRNA in cultured pulmonary artery endothelial cells. Nitric Oxide 2002, 6: 153-9.
44. Marletta, M,A. Nitric oxide synthase structure and mechanism. J Biol Chem 1993, 268: 12231-4.
45. Giaid, A. and Saleh, D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995, 333: 214-21.
46. Steudel, W., Ichinose, F., Huang, P.L. et al. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 1997, 81: 34-41.
47. Laufs, U. and Liao, J.K. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998, 273: 24266-71.
48. Shiga, N., Hirano, K., Hirano, M., Nishimura, J., Nawata, H. and Kanaide, H. Long-term inhibition of RhoA attenuates vascular contractility by enhancing endothelial NO production in an intact rabbit mesenteric artery. Circ Res 2005, 96: 1014-21.
49. Yamanouchi, D., Banno, H., Nakayama, M. et al. Hydrophilic statin suppresses vein graft intimal hyperplasia via endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg 2005, 42: 757-64.
50. Takemoto, M., Sun, J., Hiroki, J., Shimokawa, H. and Liao, J.K. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002, 106: 57-62.
51. MacLean, M.R., Herve, P., Eddahibi, S. and Adnot, S. 5- hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000, 131: 161-8.
52. Weigand, L., Sylvester, J.T. and Shimoda, L.A. Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2006, 290: L284-90.
53. Scherer, E.Q., Arnold, W. and Wangemann, P. Pharmacological reversal of endothelin-1 mediated constriction of the spiral modiolar artery: a potential new treatment for sudden sensorineural hearing loss. BMC Ear Nose Throat Disord 2005, 5: 10.
54. Losapio, J.L., Sprague, R.S., Lonigro, A.J. and Stephenson, A.H. 5,6-EET-induced contraction of intralobar pulmonary arteries depends on the activation of Rho-kinase. J Appl Physiol 2005, 99: 1391-6.
55. Koyama, M., Ito, M., Feng, J. et al. Phosphorylation of CPI-17, an inhibitory phosphoprotein of smooth muscle myosin phosphatase, by Rho-kinase. FEBS Lett 2000, 475: 197-200.
56. Pang, H., Guo, Z., Su, W., Xie, Z., Eto, M. and Gong, M.C. RhoA-Rho kinase pathway mediates thrombin- and U-46619-induced phosphorylation of a myosin phosphatase inhibitor, CPI-17, in vascular smooth muscle ceils. Am J Physiol Cell Physiol 2005, 289: C352-60.
57. Kureishi, Y., Kobayashi, S., Amano, M. et al. Rho-associated kinase directly induces smooth muscle contraction through myosin light chain phosphorylation. J Biol Chem 1997, 272: 12257-60.
58. Wang, Z., Lanner, M.C., Jin, N.J., Swartz, D., Li, L. and Rhoades, R.A. Hypoxia inhibits myosin phosphatase in pulmonary arterial smooth muscle cells. Am J Respir Cell Mol Biol 2003, 29: 465-71.
59. + channels to RhoA/Rho kinase in pulmonary vasoconstriction. Cardiovasc Res 2005, 66: 84-93.
60. Nagaoka, T., Morio, Y., Casanova, N., Bauer, N., Gebb, S., McMurtry, I. and Oka, M. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2004, 287: L665-72.
61. Kamiyama, M., Utsunomiya, K., Taniguchi, K. et al. Contribution of RhoA and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb 2003, 10: 117-23.
62. Seasholtz, T.M., Majumdar, M., Kaplan, D.D. and Brown, J.H. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999, 84: 1186-93.
63. Sauzeau, V., LeMellionnec, E., Bertoglio, J., Scalbert, E., Pacaud, P. and Loirand, G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 2001, 88: 1102-A
64. Matsumoto, Y., Uwatoku, T., Oi, K. et al. Long-term inhibition of Rho-kinase suppresses neointimal formation after stent implantation in porcine coronary arteries: involvement of multiple mechanisms. Arterioscler Thromb Vasc Biol 2004, 24: 181-6.
65. Horwitz, A.R. and Parsons, J.T. Cell migration-movin' on. Science 1999, 286: 1102-3.
66. Miyata, K., Shimokawa, H., Kandabashi, H. et al. Rho-kinase is involved in macrophage-mediated formation of coronary vascular lesions in pigs in vivo. Arterioscler Thromb Vase Biol 2000, 20: 2351-8.
67. Kimura, H., Kasahara, Y., Kurosu, K. et al. Alleviation of monocrotaline-induced pulmonary hypertension by antibodies to monocyte chemotactic and activating factor/monocyte chemoattractant protein-1. Lab Invest 1998, 78: 571-81.
68. Rothman, A., Wolner, B., Button, D. and Taylor, P. Immediate-early gene expression in response to hypertrophic and proliferative stimuli in pulmonary arterial smooth muscle cells. J Biol Chem 1994, 269: 6399-404.
69. Schermuly, R.T., Dony, E., Ghofrani, H.A. et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005, 115: 2811-21.
70. Otsuka, T., Ibuki, C., Suzuki, T. et al. Vasodilatory effect of subsequent administration of fasudil, a rho-kinase inhibitor, surpasses that of nitroglycerin at the concentric coronary stenosis in patients with stable angina pectoris. Circ J 2006, 70: 402-8.
71. Masuraoto, A., Hirooka, Y., Shimokawa, H., Hironaga, K., Setoguchi, S. and Takeshita, A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension 2001, 38: 1307-10.
72. Kishi, T., Hirooka, Y., Masumoto, A. et al. Rho-kinase inhibitor improves increased vascular resistance and impaired vasodilation of the forearm in patients with heart failure. Circulation 2005, 111: 2741-7.